Cargando…

Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes

OBJECTIVE: Rebamipide ophthalmic suspension was developed for the treatment of dry eyes and for other corneal diseases, promoting the secretion of both mucin in tear fluid and membrane-associated mucin, increasing the number of goblet cells, and restoring the barrier function of the corneal epitheli...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Yusuke, Toshida, Hiroshi, Matsuzaki, Yusuke, Matsui, Asaki, Ohta, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872273/
https://www.ncbi.nlm.nih.gov/pubmed/27257394
http://dx.doi.org/10.2147/IMCRJ.S103299
_version_ 1782432704001736704
author Hayashi, Yusuke
Toshida, Hiroshi
Matsuzaki, Yusuke
Matsui, Asaki
Ohta, Toshihiko
author_facet Hayashi, Yusuke
Toshida, Hiroshi
Matsuzaki, Yusuke
Matsui, Asaki
Ohta, Toshihiko
author_sort Hayashi, Yusuke
collection PubMed
description OBJECTIVE: Rebamipide ophthalmic suspension was developed for the treatment of dry eyes and for other corneal diseases, promoting the secretion of both mucin in tear fluid and membrane-associated mucin, increasing the number of goblet cells, and restoring the barrier function of the corneal epithelium. We report a case of a persistent corneal epithelial defect in a patient with diabetes treated with topical application of rebamipide ophthalmic suspension. CASE PRESENTATION: A 73-year-old woman had a history of type 2 diabetes for 35 years and nonproliferative diabetic retinopathy for 23 years. She presented to our department with discharge and ophthalmalgia in the left eye. A corneal ulcer was detected, and culture of corneal scrapings was performed, with Staphylococcus aureus and Streptococcus canis being isolated. The infection was treated with levofloxacin eye drops and ofloxacin ophthalmic ointment based on the sensitivity profile of the isolate. However, a corneal epithelial defect persisted for approximately 2 months despite continuing treatment with 0.1% hyaluronic acid ophthalmic suspension and 0.3% ofloxacin eye ointment. Her hemoglobin A1c was 7.3%. The persistent corneal epithelial defect showed improvement at 2 weeks after treatment with rebamipide unit dose 2% ophthalmic suspension, and it did not recur even when vitrectomy was subsequently performed for vitreous hemorrhage due to progression of diabetic retinopathy. CONCLUSION: This is the first report about efficacy of rebamipide unit dose 2% ophthalmic suspension for presenting persistent corneal epithelial defect in a patient with diabetes. In the present case, the suggested mechanisms are the following: improving the corneal barrier function, stabilization of mucin on the keratoconjunctival epithelium, and improving the wettability and stability of the tear film, which resulted in the promotion of healing of the corneal epithelial defect in a short time period.
format Online
Article
Text
id pubmed-4872273
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48722732016-06-02 Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes Hayashi, Yusuke Toshida, Hiroshi Matsuzaki, Yusuke Matsui, Asaki Ohta, Toshihiko Int Med Case Rep J Case Report OBJECTIVE: Rebamipide ophthalmic suspension was developed for the treatment of dry eyes and for other corneal diseases, promoting the secretion of both mucin in tear fluid and membrane-associated mucin, increasing the number of goblet cells, and restoring the barrier function of the corneal epithelium. We report a case of a persistent corneal epithelial defect in a patient with diabetes treated with topical application of rebamipide ophthalmic suspension. CASE PRESENTATION: A 73-year-old woman had a history of type 2 diabetes for 35 years and nonproliferative diabetic retinopathy for 23 years. She presented to our department with discharge and ophthalmalgia in the left eye. A corneal ulcer was detected, and culture of corneal scrapings was performed, with Staphylococcus aureus and Streptococcus canis being isolated. The infection was treated with levofloxacin eye drops and ofloxacin ophthalmic ointment based on the sensitivity profile of the isolate. However, a corneal epithelial defect persisted for approximately 2 months despite continuing treatment with 0.1% hyaluronic acid ophthalmic suspension and 0.3% ofloxacin eye ointment. Her hemoglobin A1c was 7.3%. The persistent corneal epithelial defect showed improvement at 2 weeks after treatment with rebamipide unit dose 2% ophthalmic suspension, and it did not recur even when vitrectomy was subsequently performed for vitreous hemorrhage due to progression of diabetic retinopathy. CONCLUSION: This is the first report about efficacy of rebamipide unit dose 2% ophthalmic suspension for presenting persistent corneal epithelial defect in a patient with diabetes. In the present case, the suggested mechanisms are the following: improving the corneal barrier function, stabilization of mucin on the keratoconjunctival epithelium, and improving the wettability and stability of the tear film, which resulted in the promotion of healing of the corneal epithelial defect in a short time period. Dove Medical Press 2016-05-10 /pmc/articles/PMC4872273/ /pubmed/27257394 http://dx.doi.org/10.2147/IMCRJ.S103299 Text en © 2016 Hayashi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
Hayashi, Yusuke
Toshida, Hiroshi
Matsuzaki, Yusuke
Matsui, Asaki
Ohta, Toshihiko
Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes
title Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes
title_full Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes
title_fullStr Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes
title_full_unstemmed Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes
title_short Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes
title_sort persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872273/
https://www.ncbi.nlm.nih.gov/pubmed/27257394
http://dx.doi.org/10.2147/IMCRJ.S103299
work_keys_str_mv AT hayashiyusuke persistentcornealepithelialdefectrespondingtorebamipideophthalmicsolutioninapatientwithdiabetes
AT toshidahiroshi persistentcornealepithelialdefectrespondingtorebamipideophthalmicsolutioninapatientwithdiabetes
AT matsuzakiyusuke persistentcornealepithelialdefectrespondingtorebamipideophthalmicsolutioninapatientwithdiabetes
AT matsuiasaki persistentcornealepithelialdefectrespondingtorebamipideophthalmicsolutioninapatientwithdiabetes
AT ohtatoshihiko persistentcornealepithelialdefectrespondingtorebamipideophthalmicsolutioninapatientwithdiabetes